Finally, in a murine model of PDAC, the disruption of CCR5/CCL5 signaling, either by reducing CCL5 production by tumor cells (shRNA) or by systemic administration of the CCR5 inhibitor TAK-779, results in decreased Treg recruitment to the tumor and smaller tumors [110] that led the authors to suggest the potential use of such an inhibitor in clinic to inhibit Treg recruitment. Here, CCL5 is linked to neoplasm.